Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laboratory Corporation of America Holdings has announced the availability of OvaSure, an ovarian cancer screening test to assess the presence of early stage ovarian cancer in high-risk women.
Subscribe to our email newsletter
According to Laboratory Corporation of America (LabCorp), in a recent study of high risk and average risk subjects, this blood test, using six biomarkers and research conducted at Yale University School of Medicine, was shown to discriminate between disease-free women and ovarian cancer patients (stage I-IV) with high specificity (99.4%) and sensitivity (95.3%).
Additional studies performed at Yale University School of Medicine demonstrate comparable findings, the company said.
Myla Lai-Goldman, executive vice president and chief medical officer of LabCorp, said: “OvaSure is a significant addition to LabCorp’s family of proteomic tests, and a major component of LabCorp’s strategy to bring the latest in diagnostic technology to women’s healthcare.”